Homozygous deletion of mouse homolog of p16/CDKN2 gene on chromosome 4 in mouse liver epithelial cells in culture

被引:0
|
作者
Miyasaka, K [1 ]
Kawauchi, S [1 ]
机构
[1] HOSHI UNIV, DEPT HYG CHEM, SHINAGAWA KU, TOKYO 142, JAPAN
关键词
mouse homolog; p16/CDKN2; immortalization; microsatellite; tumor suppressor gene;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The culture of hepatocytes isolated from C3H mouse liver results in the spontaneous development of colonies of liver epithelial cells that possess some features of the hepatocytes. These liver epithelial cells frequently have a loss of chromosome 4, and become neoplasms which are hepatocellular carcinomas by transfection with the activated c-Ha-ras gene, The suppression of malignant phenotypes by mouse chromosome 4 has already been shown by fusion between normal and malignant mouse cells, We established a total of six liver epithelial cell lines from C3H mice in order to investigate the presence of a tumor suppressor gene(s) on chromosome 4 in mouse hepatocarcinogenesis, and performed an allelotype analysis in seven microsatellites on chromosome 4 by the comparative multiplex PCR method. The result of analysis revealed that three of the six liver epithelial cells had allelic imbalances in four microsatellite loci, especially, two liver epithelial cell lines showed homozygous deletion in the D4MIT177 locus. Then, we investigated the status of the mouse homolog of p16/CDKN2 gene (mouse p16) on chromosome 4 by the comparative multiplex PCR method, and detected the homozygous deletion in two liver epithelial cell lines. Our result thus supports the theory that alterations of tumor suppressor gene(s) located on chromosome 4 may play a role in mouse hepatocarcinogenesis. Mouse p16, which is an inhibitor of cyclin dependent kinase 4, may suppress the cancer development in mouse hepatocarcinogenesis, or suppress liver cell immortalization.
引用
收藏
页码:345 / 349
页数:5
相关论文
共 50 条
  • [31] Loss of either p16/CDKN2 or retinoblastoma is required for overcoming senescence in human prostate epithelial cells.
    Jarrard, DF
    Yeager, TR
    Nassif, N
    Sandefur, CE
    Reznikoff, CA
    [J]. JOURNAL OF UROLOGY, 1998, 159 (05): : 71 - 71
  • [32] Expression of p16 gene (CDKN2) increased cell adhesion of breast cancers.
    Yang, L
    Jin, G
    Shi, Y
    Bai, J
    Nobori, T
    Sung, P
    Yu, BF
    [J]. CANCER GENE THERAPY, 1996, 3 (06) : P112 - P112
  • [33] Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens
    Jacqueline E. Calvano
    Elisa B. Rush
    Lee K. Tan
    Paul Peter Rosen
    Patrick I. Borgen
    Kimberly J. Van Zee
    [J]. Annals of Surgical Oncology, 1997, 4 : 416 - 420
  • [34] Focal distribution of p16/CDKN2 gene mutations within individual prostate carcinomas
    Konishi, N
    Hiasa, Y
    Tao, M
    Matsuda, H
    Nakamura, M
    Yane, K
    Kitahori, Y
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (03) : 549 - 554
  • [35] REPLACEMENT OF THE P16/CDKN2 GENE SUPPRESSES HUMAN GLIOMA CELL-GROWTH
    ARAP, W
    NISHIKAWA, R
    FURNARI, FB
    CAVENEE, WK
    HUANG, HJS
    [J]. CANCER RESEARCH, 1995, 55 (06) : 1351 - 1354
  • [36] Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens
    Calvano, JE
    Rush, EB
    Tan, LK
    Rosen, PP
    Borgen, PI
    VanZee, KJ
    [J]. ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (05) : 416 - 420
  • [37] Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas
    Tang, Vivian
    Lu, Rufei
    Mirchia, Kanish
    Van Ziffle, Jessica
    Devine, Patrick
    Lee, Julieann
    Phillips, Joanna J. J.
    Perry, Arie
    Raleigh, David R. R.
    Lucas, Calixto-Hope G.
    Solomon, David A. A.
    [J]. ACTA NEUROPATHOLOGICA, 2023, 145 (04) : 497 - 500
  • [38] Relationship between exon deletion frequency of CDKN2/P16 and pathological type,metastasis,sex in osteosarcoma
    逄育
    苏佳灿
    康一凡
    陈舰
    陈永裕
    [J]. 中国组织工程研究, 2002, (22) : 3450 - 3451
  • [39] P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas
    Vij, Meenakshi
    Cho, Benjamin B. B.
    Yokoda, Raquel T. T.
    Rashidipour, Omid
    Umphlett, Melissa
    Richardson, Timothy E. E.
    Tsankova, Nadejda M. M.
    [J]. ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2023, 11 (01)
  • [40] P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas
    Meenakshi Vij
    Benjamin B. Cho
    Raquel T. Yokoda
    Omid Rashidipour
    Melissa Umphlett
    Timothy E. Richardson
    Nadejda M. Tsankova
    [J]. Acta Neuropathologica Communications, 11